Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Deere & Company (DE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Deere & Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Deere & Company trades at $594.6 (market cap $162.94B). The key difference: Deere & Company is far larger — about 36.3× ACADIA Pharmaceuticals Inc.'s market cap, and Deere & Company pays a 1.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DE | |
|---|---|---|
Market Cap | $4.49B | $162.94B |
Sector | Health | Industrials |
52-Week High | $28.06 | $662.49 |
52-Week Low | $20.06 | $439.11 |
Enterprise Value | $3.69B | $217.76B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Deere & Company (DE) trades at $603.61, down 2.84% on the day, with the stock showing strong technical momentum despite recent volatility. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $6.55 exceeding estimates by 15%. Fundamentals remain solid with 10.33% net margins and 18.51% ROE, though revenue declined to $44.67B in 2025. Analyst consensus points to 39% buy ratings with a $666.08 price target, representing 10% upside potential.
DE presents a mixed outlook with strong operational execution offset by cyclical headwinds in agricultural equipment demand. The precision agriculture platform offers growth potential, but investors face risks from economic sensitivity and margin pressure. Current valuation at 36x P/E appears elevated relative to historical norms, requiring continued earnings growth to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
